MedTrace Logo

Clinical Study of GPA33-specific PET/CT for the Diagnosis of Colorectal Cancer

NCT06203587 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-02-20

No results posted yet for this study

Summary

In this study, we will first investigate the imaging safety and feasibility of \[68Ga\]Ga-NOTA-WWH347 and \[18F\]F-H3RESCA-WWH347 PET/CT in patients with primary and/or metastatic colorectal cancers. The second goal of the study is to preliminarily investigate the diagnostic efficacy (e.g., sensitivity and specificity) of \[68Ga\]Ga-NOTA-WWH347 and \[18F\]F-H3RESCA-WWH347 PET/CT in patients with primary and/or metastatic colorectal cancers. This study will provide a new method for the noninvasive target-specific diagnosis of colorectal cancer, and provide an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment.

Conditions

  • Positron-Emission Tomography
  • Colorectal Neoplasms

Interventions

RADIATION

[68Ga]Ga-NOTA-WWH347 or [18F]F-H3RESCA-WWH347

The dose of \[68Ga\]Ga-NOTA-WWH347 or \[18F\]F-H3RESCA-WWH347, calculated from the patient's body weight, was 1.8-3.7 MBq \[0.05-0.1 mCi\]/kg, and was administered as an intravenous push, with a single dose given once.

Sponsors & Collaborators

  • Huashan Hospital

    lead OTHER

Principal Investigators

  • Fang Xie, PhD · Huashan Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-09-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203587 on ClinicalTrials.gov